Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Herantis Pharma Plc, Press release, 8 October 2024 at 8:00 AM EEST
Herantis Pharma to host R&D webinar on October 23, 2024
Link to the R&D webinar (10:00-11:00 EET/9:00-10:00 CET): https://herantis.videosync.fi/webinar-10-2024
Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease, will host an R&D webinar on Wednesday October 23rd, 2024. Investors, analysts, partners, media and anyone interested in Herantis and our promising HER-096 development program for Parkinson’s disease are invited to join this virtual event.
Agenda for Herantis’ R&D webinar:
1) Insights into mechanism of action of HER-096
2) HER-096 preclinical evidence
3) HER-096 clinical data
4) Development plan
5) Herantis as an investment opportunity
6) Q&A
R&D Webinar Information:
A webinar (in English) will be held Wednesday October 23rd, 2024, at 10:00 EET / 9:00 CET.
Please use the following link to register for this event: https://herantis.videosync.fi/webinar-10-2024
After registering, you will receive a confirmation email containing information about joining the webcast. Questions can be submitted throughout the webcast event. The recording of the webcast will be available on https://herantis.com/news-events/video-presentations/ following the event.
About HER-096:
HER-096 is an engineered peptidomimetic molecule designed to mimic the activity of CDNF, a protein that promotes cell survival and functional recovery of neurons. HER-096 modulates the Unfolded Protein Response (UPR) pathway, the regulation of which is essential in restoring the cell protein balance (proteostasis) and preventing the processes leading to, e.g., cytotoxic protein aggregation and neuronal cell death in the brain. In addition, HER-096 alleviates inflammation in the affected brain area. Thanks to its multimodal mechanism of action, Herantis’ HER-096 has the potential to stop the progression of Parkinson’s disease and significantly improve patients’ quality of life.
For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com
Certified Advisor:
UB Corporate Finance Ltd
Tel.: +358 9 25 380 225
E-mail: ubcf@unitedbankers.fi
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The primary aim of the ongoing Phase 1b clinical trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in healthy volunteers.
Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com